Top

Published in:

01-01-2020 | Blepharospasm | Original Communication

Treatment of blepharospasm and Meige’s syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice

Authors: Angela Jochim, Tobias Meindl, Christoph Huber, Tobias Mantel, Silke Zwirner, Florian Castrop, Bernhard Haslinger

Published in: Journal of Neurology | Issue 1/2020

Abstract

Introduction

Thirty years after their approval, botulinum toxin injections still are the first-line therapy for blepharospasm. The aim of our study was to analyze long-term data concerning safety and efficacy in a large cohort over decades.

Methods

Treatment data of all patients with blepharospasm and Meige´s syndrome in our outpatient clinic having undergone at least three subsequent treatment sessions with current onabotulinumtoxinA or abobotulinumtoxin A were analyzed with respect to the course of dose, effect duration, side effects, patients´ satisfaction and occurrence/reasons for treatment discontinuation.

Results

The observation period was up to 18 years for onabotulinumtoxinA and 29 years for abobotulinumtoxinA with a total of 1778 and 9319 treatment sessions in 69 patients with onabotulinumtoxinA, 281 with abobotulinumtoxin A and 2 of these having used both products. The dose increased in the first years followed by a stable dose in the following years. The mean dose was 39.1/198.7 mouse units (onabotulinumtoxinA/abobotulinumtoxinA). In over 25% of all sessions, inhibition of the eyelid opening was effectively treated with pretarsal injections. The most common adverse events included ptosis (4%/5%), epiphora/sicca (4%/5%), double vision (1%/1%) and facial asymmetry (1%/1%). Reasons for therapy discontinuation were change to a nearby doctor, age, other diseases, spontaneous improvement, side effects or possible treatment failure. Only one patient was tested positive for neutralizing antibodies against botulinum toxin A.

Conclusion

The treatment of blepharospasm and Meige’s syndrome with onabotulinumtoxinA and abobotulinumtoxinA is safe and effective, also over a long observation period of up to 29 years.

Available only for authorised users

Valls-Sole J, Defazio G (2016) Blepharospasm: update on epidemiology, clinical aspects, and pathophysiology. Front Neurol 7:45. https://doi.org/10.3389/fneur.2016.00045 CrossRefPubMedPubMedCentral

Aramideh M, Ongerboer de Visser BW, Koelman JH, Bour LJ, Devriese PP, Speelman JD (1994) Clinical and electromyographic features of levator palpebrae superioris muscle dysfunction in involuntary eyelid closure. Mov Disord 9(4):395–402. https://doi.org/10.1002/mds.870090404 CrossRefPubMed

Dutton JJ, Fowler AM (2007) Botulinum toxin in ophthalmology. Surv Ophthalmol 52(1):13–31. https://doi.org/10.1016/j.survophthal.2006.10.003 CrossRefPubMed

Molloy A, Williams L, Kimmich O, Butler JS, Beiser I, McGovern E, O'Riordan S, Reilly RB, Walsh C, Hutchinson M (2015) Sun exposure is an environmental factor for the development of blepharospasm. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2014-310266 CrossRefPubMed

Jochim A, Li Y, Gora-Stahlberg G, Mantel T, Berndt M, Castrop F, Dresel C, Haslinger B (2018) Altered functional connectivity in blepharospasm/orofacial dystonia. Brain Behav 8(1):e00894. https://doi.org/10.1002/brb3.894 CrossRefPubMed

Defazio G, Hallett M, Jinnah HA, Conte A, Berardelli A (2017) Blepharospasm 40 years later. Mov Disord 32(4):498–509. https://doi.org/10.1002/mds.26934 CrossRefPubMedPubMedCentral

Albanese A, Di Giovanni M, Lalli S (2019) Dystonia: diagnosis and management. Eur J Neurol 26(1):5–17. https://doi.org/10.1111/ene.13762 CrossRefPubMed

Jochim A, Meindl T, Mantel T, Zwirner S, Zech M, Castrop F, Haslinger B (2019) Treatment of cervical dystonia with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice. J Neurol 266(8):1879–1886. https://doi.org/10.1007/s00415-019-09349-2 CrossRefPubMed

Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60(7):1186–1188CrossRef

10.

Allergan Pharmaceuticals Ireland I (2018) Fachinformation BOTOX^® 50/100/200 Allergan-Einheiten; Approval number: 55006.00.00. https://www.fachinfo.de/pdf/020408. Accessed 19 June 2019

11.

Ipsen Pharma GmbH Ettlingen Germany G (March 2018) Fachinformation (Zusammenfassung der Merkmale des Arzneimittels) Dysport^® 300 Einheiten/500 Einheiten; Approval number: 50586.00.00. https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/sites/21/2018/11/14125820/Fachinformation-Dysport-2018.pdf. Accessed 19 June 2019

12.

Ramirez-Castaneda J, Jankovic J (2014) Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon 90:344–348. https://doi.org/10.1016/j.toxicon.2014.07.009 CrossRefPubMed

13.

Czyz CN, Burns JA, Petrie TP, Watkins JR, Cahill KV, Foster JA (2013) Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome. Am J Ophthalmol 156(1):173 e172–177 e172. https://doi.org/10.1016/j.ajo.2013.02.001 CrossRef

14.

Kollewe K, Mohammadi B, Kohler S, Pickenbrock H, Dengler R, Dressler D (2015) Blepharospasm: long-term treatment with either Botox(R), Xeomin(R) or Dysport(R). J Neural Transm (Vienna) 122(3):427–431. https://doi.org/10.1007/s00702-014-1278-z CrossRef

15.

Ababneh OH, Cetinkaya A, Kulwin DR (2014) Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol 42(3):254–261. https://doi.org/10.1111/ceo.12165 CrossRefPubMed

16.

Cillino S, Raimondi G, Guepratte N, Damiani S, Cillino M, Di Pace F, Casuccio A (2010) Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes. Eye (Lond) 24(4):600–607. https://doi.org/10.1038/eye.2009.192 CrossRef

17.

Streitova H, Bares M (2014) Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years. Acta Neurol Belg 114(4):285–291. https://doi.org/10.1007/s13760-014-0285-z CrossRefPubMed

18.

Calace P, Cortese G, Piscopo R, Della Volpe G, Gagliardi V, Magli A, De Berardinis T (2003) Treatment of blepharospasm with botulinum neurotoxin type A: long-term results. Eur J Ophthalmol 13(4):331–336CrossRef

19.

Gil Polo C, Rodriguez Sanz MF, Berrocal Izquierdo N, Castrillo Sanz A, Gutierrez Rios R, Zamora Garcia MI, Mendoza Rodriguez A, Duarte Garcia-Luis J (2013) Blepharospasm and hemifacial spasm: long-term treatment with botulinum toxin. Neurologia 28(3):131–136. https://doi.org/10.1016/j.nrl.2012.03.009 CrossRefPubMed

20.

Vogt T, Lussi F, Paul A, Urban P (2008) Long-term therapy of focal dystonia and facial hemispasm with botulinum toxin A. Nervenarzt 79(8):912–917. https://doi.org/10.1007/s00115-008-2486-2 CrossRefPubMed

21.

Mejia NI, Vuong KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20(5):592–597. https://doi.org/10.1002/mds.20376 CrossRefPubMed

22.

Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchowersky O (2002) Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Mov Disord 17(6):1288–1293. https://doi.org/10.1002/mds.10252 CrossRefPubMed

23.

Gill HS, Kraft SP (2010) Long-term efficacy of botulinum a toxin for blepharospasm and hemifacial spasm. Can J Neurol Sci 37(5):631–636CrossRef

24.

Silveira-Moriyama L, Goncalves LR, Chien HF, Barbosa ER (2005) Botulinum toxin a in the treatment of blepharospasm: a 10-year experience. Arq Neuropsiquiatr 63(2A):221–224CrossRef

25.

Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A (2009) Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res 15(3):224–231. https://doi.org/10.1007/s12640-009-9023-3 CrossRefPubMed

26.

Wakakura M, Yamagami A, Iwasa M (2018) Blepharospasm in Japan: a clinical observational study from a large referral hospital in Tokyo. Neuroophthalmology 42(5):275–283. https://doi.org/10.1080/01658107.2017.1409770 CrossRefPubMedPubMedCentral

27.

Hellman A, Torres-Russotto D (2015) Botulinum toxin in the management of blepharospasm: current evidence and recent developments. Ther Adv Neurol Disord 8(2):82–91. https://doi.org/10.1177/1756285614557475 CrossRefPubMedPubMedCentral

28.

Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G (2009) Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord 24(3):407–413. https://doi.org/10.1002/mds.22368 CrossRefPubMed

29.

Lepore V, Defazio G, Acquistapace D, Melpignano C, Pomes L, Lamberti P, Livrea P, Ferrari E (1995) Botulinum A toxin for the so-called apraxia of lid opening. Mov Disord 10(4):525–526. https://doi.org/10.1002/mds.870100425 CrossRefPubMed

30.

Defazio G, Ribatti D, Nico B, Ricchiuti F, De Salvia R, Roncali L, Livrea P (1997) Endocytosis of horseradish peroxidase by brain microvascular and umbilical vein endothelial cells in culture: an ultrastructural and morphometric study. Brain Res Bull 43(5):467–472CrossRef

31.

Lee S, Park S, Lew H (2018) Long-term efficacy of botulinum neurotoxin-A treatment for essential blepharospasm. Korean J Ophthalmol 32(1):1–7. https://doi.org/10.3341/kjo.2017.0030 CrossRefPubMedPubMedCentral

32.

Levy RL, Berman D, Parikh M, Miller NR (2006) Supramaximal doses of botulinum toxin for refractory blepharospasm. Ophthalmology 113(9):1665–1668. https://doi.org/10.1016/j.ophtha.2006.03.055 CrossRefPubMed

33.

Pang AL, O'Day J (2006) Use of high-dose botulinum A toxin in benign essential blepharospasm: is too high too much? Clin Exp Ophthalmol 34(5):441–444. https://doi.org/10.1111/j.1442-9071.2006.01236.x CrossRefPubMed

34.

Snir M, Weinberger D, Bourla D, Kristal-Shalit O, Dotan G, Axer-Siegel R (2003) Quantitative changes in botulinum toxin a treatment over time in patients with essential blepharospasm and idiopathic hemifacial spasm. Am J Ophthalmol 136(1):99–105CrossRef

35.

Colosimo C, Tiple D, Berardelli A (2012) Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res 22(4):265–273. https://doi.org/10.1007/s12640-012-9314-y CrossRefPubMed

Title: Treatment of blepharospasm and Meige’s syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice
Authors: Angela Jochim
Tobias Meindl
Christoph Huber
Tobias Mantel
Silke Zwirner
Florian Castrop
Bernhard Haslinger
Publication date: 01-01-2020
Publisher: Springer Berlin Heidelberg
Keywords: Blepharospasm
Blepharospasm
Dystonia
Botulinum Toxin
Published in: Journal of Neurology / Issue 1/2020
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-019-09581-w

At a glance: The STEP trials

Springer Medicine

Treatment of blepharospasm and Meige’s syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice

Abstract

Introduction

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study

Correction to: Longitudinal multi-modal muscle-based biomarker assessment in motor neuron disease

“Thalamic aphasia” after stroke is associated with left anterior lesion location

Apathy as a behavioural marker of cognitive impairment in Parkinson’s disease: a longitudinal analysis

Risk factors for lymphopenia in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate

Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen